Featured Article: Serum [Met⁵]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone

Keyphrases

• Enkephalin 100%
• Low-dose Naltrexone 100%
• Multiple Sclerosis 100%
• Opioid Growth Factor 66%
• Experimental Autoimmune Encephalomyelitis 33%
• Factor Level 25%
• Endogenous Opioids 25%
• Opioid Growth Factor Receptor (OGFr) 16%
• Response to Therapy 16%
• β-endorphin 16%
• Multiple Sclerosis Treatment 16%
• Experimental Autoimmune Encephalomyelitis Mice 16%
• Inflammation 8%
• Blood Levels 8%
• Clinical Disease 8%
• Mouse Model 8%
• Cell Proliferation 8%
• Opioid Receptors 8%
• Naltrexone 8%
• Autoimmune Disease 8%
• Naltrexone Treatment 8%
• Temporal Patterns 8%
• Serum Levels 8%
• Animal Data 8%
• Crohn's Disease 8%
• Human Data 8%
• Fibromyalgia 8%
• White Blood Cell Count 8%
• Neurological Impairment 8%
• Heat Sensitivity 8%
• Tactile Sensitivity 8%
• Biofeedback 8%
• Multiple Responses 8%
• Novel Biomarkers 8%
• Production Increase 8%
• Behavioural Signs 8%
• Chronic Progressive 8%
• Autoimmune Response 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Naltrexone 100%
• Enkephalin 100%
• Multiple Sclerosis 100%
• Growth Factor 66%
• Experimental Autoimmune Encephalomyelitis 50%
• Endorphin 41%
• Biological Marker 33%
• Growth Factor Receptor 16%
• Inflammation 8%
• Opiate Receptor 8%
• Mouse Model 8%
• Preclinical Study 8%
• Fibromyalgia 8%
• Crohn's Disease 8%
• Autoimmune Disease 8%
• Diseases 8%

Neuroscience

• Naltrexone 100%
• Enkephalin 100%
• Multiple Sclerosis 100%
• Growth Factor 66%
• Experimental Autoimmune Encephalomyelitis 50%
• Endorphin 41%
• Growth Factor Receptor 16%
• Leukocyte 8%
• Cell Proliferation 8%
• Autoimmune Disease 8%
• Receptor 8%
• Fibromyalgia 8%
• Biofeedback 8%